What Is the Appropriate Approach to Treating Women With Incurable Cervical Cancer?

被引:19
作者
Ramondetta, Lois [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[2] Harris Hlth Syst, Lyndon Baines Johnson Hosp, Div Gynecol Oncol, Houston, TX USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 03期
关键词
GYNECOLOGIC-ONCOLOGY-GROUP; QUALITY-OF-LIFE; SQUAMOUS-CELL-CARCINOMA; PHASE-II TRIAL; OVARIAN-CANCER; BETA-BLOCKERS; BREAST-CANCER; PALLIATIVE CARE; SUPPORTIVE CARE; TUMOR-GROWTH;
D O I
10.6004/jnccn.2013.0044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Women should not die of cervical cancer ... but they do. Most cases of cervical cancer are preventable and, if caught early, highly curable. Despite this, cervical cancer is the second most common cause of cancer death in women worldwide. Unfortunately, cure is less likely when the disease is diagnosed at an advanced stage. Treatment of locally advanced disease often has serious lifelong side effects, including cystitis, proctitis, intestinal strictures, fistulas, vaginal agglutination/sexual dysfunction, and chronic pain. Unresectable recurrent disease may be associated with all these symptoms, in addition to disturbing malodorous discharge and bleeding and a life expectancy of less than 6 to 10 months. Supportive/palliative care interventions are needed at diagnosis and recurrence. Honest, conflict-free conversations about potential for response and expectations are needed for women with recurrent disease to help preserve and improve quality of life and avoid treatments that offer no benefit. Aims of trial design should include not only molecular targeting but also supportive care objectives, such as reducing pain, anxiety, depression, cachexia, and fatigue. A p-adrenergic blockade could potentially be part of these intervention trials. This article addresses the following questions and issues: whether therapeutic treatment of incurable cervical cancer is ever appropriate, the common symptoms of recurrent cervical cancer, the quantifying benefits of treatment, decision aids in treatment planning, doctor-patient candor, and integrating psychosocial factors into treatment. (JNCCN 2013;11:348-355)
引用
收藏
页码:348 / 355
页数:8
相关论文
共 78 条
[1]   Intercepting neoplastic progression in lung malignancies via the beta adrenergic (β-AR) pathway: Implications for anti-cancer drug targets [J].
Al-Wadei, Hussein A. N. ;
Ullah, Mohammad F. ;
Al-Wadei, Mohammed H. .
PHARMACOLOGICAL RESEARCH, 2012, 66 (01) :33-40
[2]  
[Anonymous], WHO Definition of Palliative Care
[3]   Opinion - The influence of bio-behavioural factors on tumour biology: pathways and mechanisms [J].
Antoni, MH ;
Lutgendorf, SK ;
Cole, SW ;
Dhabhar, FS ;
Sephton, SE ;
McDonald, PG ;
Stefanek, M ;
Sood, AK .
NATURE REVIEWS CANCER, 2006, 6 (03) :240-248
[4]  
ASCO, CLIN TOOLS RES LUNG
[5]  
Back Anthony L, 2003, Ann Intern Med, V138, P439
[6]   End of life care for women with gynecologic cancers [J].
Barbera, L. ;
Elit, L. ;
Krzyzanowska, M. ;
Saskin, R. ;
Bierman, A. S. .
GYNECOLOGIC ONCOLOGY, 2010, 118 (02) :196-201
[7]   Reliability and validity of the functional assessment of cancer therapy-ovarian [J].
Basen-Engquist, K ;
Bodurka-Bevers, D ;
Fitzgerad, MA ;
Webster, K ;
Cella, D ;
Hu, SH ;
Gershenson, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1809-1817
[8]   Lymphedema after gynecological cancer treatment - Prevalence, correlates, and supportive care needs [J].
Beesley, Vanessa ;
Janda, Monika ;
Eakin, Elizabeth ;
Obermair, Andreas ;
Battistutta, Diana .
CANCER, 2007, 109 (12) :2607-2614
[9]   Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety [J].
Bonifazi, Martina ;
Rossi, Marta ;
Moja, Lorenzo ;
Scigliano, Vincenzo Davide ;
Franchi, Matteo ;
La Vecchia, Carlo ;
Zocchetti, Carlo ;
Negri, Eva .
ONCOLOGIST, 2012, 17 (01) :117-124
[10]  
Burke Catherine, 2005, Clin J Oncol Nurs, V9, P295, DOI 10.1188/05.CJON.295-297